About 

La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Universe Pharmaceuticals a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Universe Pharmaceuticals..

Universe Pharmaceuticals (NASDAQ:UPC) Azioni, Catena delle Opzioni

Universe Pharmaceuticals

Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals Inc

UNI-PRESIDENT C/H UNS/ADR by Uni-President China Holdings Ltd.

Uni-President China Holdings Ltd

UNIVERSAL POTASH CORP by Universal Potash Corp.

Universal Potash Corp

Earnings

Earnings Misses

News

CHRD

Chord Energy Q3 2024 Adj. EPS $3.40 Misses $3.78 Estimate, Sales $1.121B Miss $1.302B Estimate

Deluxe (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLX#NYSE">DLX</a>) reported quarterly earnings of $0.84 per share which beat the analyst consensus estimate of $0.74 by 13.51 percent. The company reported quarterly sales of $528.40 million which beat the analyst consensus estimate of $525.83 million by 0.49 percent. This is a 1.75 percent decrease over sales of $537.80 million the same period last year.

Earnings Beats

Deluxe Q3 2024 Adj EPS $0.84 Beats $0.74 Estimate, Sales $528.40M Beat $525.83M Estimate

Blend Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLND#NYSE">BLND</a>) reported quarterly sales of $45.184 million which beat the analyst consensus estimate of $41.906 million by 7.82 percent. This is a 11.32 percent increase over sales of $40.591 million the same period last year.

BLND

Blend Labs Q3 Sales $45.184M Beat $41.906M Estimate

Astronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRO#NASDAQ">ATRO</a>) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $0.08 by 525 percent. The company reported quarterly sales of $203.700 million which beat the analyst consensus estimate of $198.610 million by 2.56 percent. This is a 25.03 percent increase over sales of $162.922 million the same period last year.

ATRO

Astronics Q3 2024 GAAP EPS $(0.34) Misses $0.08 Estimate, Sales $203.700M Beat $198.610M Estimate

Host Hotels &amp; Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HST#NASDAQ">HST</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.35 by 2.86 percent. This is a 12.2 percent decrease over earnings of $0.41 per share from the same period last year. The company reported quarterly sales of $1.32 billion which beat the analyst consensus estimate of $1.29 billion by 1.85 percent. This is a 8.65 percent increase over sales of $1.21 billion the same period last year.

Host Hotels & Resorts Q3 FFO $0.36 Beats $0.35 Estimate, Sales $1.32B Beat $1.29B Estimate

"We delivered solid third quarter and year-to-date adjusted earnings resulting from infrastructure investments and disciplined cost control. As a result of this solid execution, we expect to deliver 2024 adjusted earnings within a range of $4.55 to $4.69 per share. Looking ahead, we expect our 2025 earnings per share to be in the range of $4.85 to $5.05 per share, with the midpoint representing a 7.1% increase over the midpoint of our 2024 adjusted guidance range. Further, we continue to see significant opportunity for earnings growth in the years ahead as we focus on meeting our customers' growing needs for safe, reliable, affordable and cleaner energy," said Martin J. Lyons, Jr., chairman, president and chief executive officer of Ameren Corporation. "Through consistent execution of our long-term strategy, we expect to drive sustainable earnings and dividend growth for our shareholders."

Guidance

Ameren Sees FY24 Adjusted Diluted EPS Guidance Range Established At $4.55-$4.69 Vs $4.62 Est.; FY25 Diluted EPS Guidance Range Established At $4.85-$5.05 Vs $4.91 Est.

Veeco Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VECO#NASDAQ">VECO</a>) is looking for Q4 GAAP EPS of $0.18-0.27 vs $0.28 analyst estimate..

VECO

Veeco Instruments Sees Q4 GAAP EPS $0.18-0.27 vs $0.28 Est

American Coastal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.35 by 54.29 percent. The company reported quarterly sales of $82.136 million which missed the analyst consensus estimate of $84.514 million by 2.81 percent. This is a 47.18 percent increase over sales of $55.808 million the same period last year.

ACIC

American Coastal Q3 2024 Adj. EPS $0.54 Beats $0.35 Estimate, Sales $82.136M Miss $84.514M Estimate

Veeco Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VECO#NASDAQ">VECO</a>) is looking for Q4 Adj EPS of $0.35-0.45 vs $0.46 analyst estimate. seessales of $165.000 million-185.000 million vs $182.98 million estimate.

Veeco Instruments Sees Q4 Adj EPS $0.35-0.45 vs $0.46 Est; Sees Sales $165.000M-185.000M vs $182.98M Est

Quantum Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) reported quarterly losses of $(0.06) per share. This is a 40 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $101.000 thousand which missed the analyst consensus estimate of $300.000 thousand by 66.33 percent. This is a 100.26 percent increase over sales of $50.435 thousand the same period last year.

QUBT

Quantum Computing Q3 2024 GAAP EPS $(0.06) Up From $(0.10) YoY, Sales $101.000K Miss $300.000K Estimate

Sterling Infrastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRL#NASDAQ">STRL</a>) raises FY2024 GAAP EPS guidance from $5.60-5.75 to $5.85-6.00 vs $5.67 analyst estimate. Narrows FY2024 sales outlook from $2.15 billion-2.23 billion to $2.15 billion-2.17 billion vs $2.17 billion estimate.

STRL

Sterling Infrastructure Raises FY2024 GAAP EPS Guidance from $5.60-5.75 to $5.85-6.00 vs $5.67 Est; Narrows FY2024 Sales Guidance from $2.15B-2.23B to $2.15B-2.17B vs $2.17B Est

Tenaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TS#NYSE">TS</a>) reported quarterly earnings of $0.81 per share which beat the analyst consensus estimate of $0.66 by 22.73 percent. The company reported quarterly sales of $2.915 billion which beat the analyst consensus estimate of $2.771 billion by 5.20 percent. This is a 9.98 percent decrease over sales of $3.238 billion the same period last year.

Tenaris Q3 2024 Adj. EPS $0.81 Beats $0.66 Estimate, Sales $2.915B Beat $2.771B Estimate

Sinclair Broadcast Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBGI#NASDAQ">SBGI</a>) reported quarterly earnings of $1.43 per share which beat the analyst consensus estimate of $0.98 by 45.92 percent. This is a 293.24 percent increase over losses of $(0.74) per share from the same period last year. The company reported quarterly sales of $917.00 million which missed the analyst consensus estimate of $923.00 million by 0.65 percent. This is a 19.56 percent increase over sales of $767.00 million the same period last year.

SBGI

Sinclair Broadcast Group Q3 EPS $1.43 Beats $0.98 Estimate, Sales $917.00M Miss $923.00M Estimate

DoubleVerify Sees Q4 2024 Revenue $194M-$200M Vs $204.7M Estimate; Sees FY24 Revenue $660M-$666M Vs $670.45M Estimate

Ameren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>) reported quarterly earnings of $1.87 per share which missed the analyst consensus estimate of $1.93 by 3.11 percent. This is unchanged from the same period last year. The company reported quarterly sales of $2.17 billion which met the analyst consensus estimate. This is a 5.49 percent increase over sales of $2.06 billion the same period last year.

Ameren Q3 Adj $1.87 Misses $1.93 Estimate, Sales $2.17B Inline

WIIM

BMBL

Bumble shares are trading higher following a Q3 revenue beat.

Joby Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.19) by 10.53 percent. The company reported quarterly sales of $28.000 thousand which missed the analyst consensus estimate of $43.000 thousand by 34.88 percent.

JOBY

Joby Aviation Q3 2024 GAAP EPS $(0.21) Misses $(0.19) Estimate, Sales $28.000K Miss $43.000K Estimate

Primerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRI#NYSE">PRI</a>) reported quarterly earnings of $5.16 per share which beat the analyst consensus estimate of $4.81 by 7.28 percent. The company reported quarterly sales of $774.13 million which beat the analyst consensus estimate of $745.32 million by 3.87 percent. This is a 10.99 percent increase over sales of $697.50 million the same period last year.

Primerica Q3 2024 Adj EPS $5.16 Beats $4.81 Estimate, Sales $774.13M Beat $745.32M Estimate

Superior Gr of Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGC#NASDAQ">SGC</a>) affirms FY2024 GAAP EPS guidance from $0.73-0.79 to $0.73-0.79 vs $0.74 analyst estimate. Affirms FY2024 sales outlook from $563.00 million-570.00 million to $563.00 million-570.00 million vs $564.22 million estimate.

Superior Gr of Cos Affirms FY2024 GAAP EPS Guidance to $0.73-0.79 vs $0.74 Est; Affirms FY2024 Sales Guidance to $563.00M-570.00M vs $564.22M Est

Arm Holdings Plc &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) reported second-quarter financial results after the market close on Wednesday. Here&#8217;s a look at the <a href="https://www.benzinga.com/pressreleases/24/11/b41786531/arm-holdings-plc-reports-results-for-the-second-quarter-of-the-financial-year-ended-2025">key metrics from the quarter</a>.
Q2 Earnings: Arm reported second-quarter revenue of $844 million, beating analyst <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $808.37 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The chip designer reported adjusted earnings of 30 cents per share, beating analyst estimates of 26 cents per share.
Total revenue was up 5% year-over-year, driven by record levels of royalty revenue, which was up 23% year-over-year. Royalty revenue growth was primarily driven by continued adoption of Armv9, as well as an overall smartphone market recovery.
Annualized contract value (ACV) was up 13% year-over-year to $1.25 billion. Arm said free cash flow was negative $65 million in the quarter. The company ended the period with $2.36 billion in cash, cash equivalents and short-term investments.
"Demand for our high-performance Armv9 and CSS compute platforms continues to exceed expectations, and to accelerate our licensing and royalty revenue growth. AI everywhere is generating new opportunities for the Arm compute platform from the cloud to the edge,&#8221; said&nbsp;Rene Haas, CEO of Arm Holdings.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41784504/trumps-win-sends-indices-to-record-highs-financials-small-caps-surge-bitcoin-tops-75-000-w">Trump&#8217;s Win Sends Indices To Record Highs; Financials, Small Caps Surge, Bitcoin Tops $75,000: What&#8217;s Driving Markets Wednesday?</a>
Outlook:&nbsp;Arm sees third-quarter revenue of $780 million to $830 million. The company expects third-quarter adjusted earnings to be between 23 cents and 27 cents per share versus estimates of 21 cents per share.
Arm also reiterated full-year guidance. The company continues to expect full-year revenue of $3.8 billion to $4.1 billion. Arm expects full-year adjusted earnings to be between $1.45 and $1.65 per share. 
Management will hold a conference call with analysts and investors at 5 p.m. ET. 
ARM Price Action: <a href="https://www.benzinga.com/quote/ARM" target="_blank" rel="noreferrer noopener">Arm shares</a> were down 1.85% in after-hours, trading at $142 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Shutterstock.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534;WATCH LIVE: Arm Holdings Q2 2025 Earnings Call &#x7C; $ARM" width="500" height="281" src="https://www.youtube.com/embed/jbop4upn9GU?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>

Global

After-Hours Center

Movers

Arm Holdings Q2 Earnings: Revenue Beat, EPS Beat, AI Creating New Opportunities And More

Universe Pharmaceuticals (UPC) has released an update. Universe Pharmaceuticals INC successfully completed a public offering on July 15, 2024, rais...

Universe Pharmaceuticals Raises $25 Million in Offering

Universe Pharmaceuticals (UPC) has released an update. Universe Pharmaceuticals Inc announces its upcoming annual general meeting scheduled for Sep...

Universe Pharmaceuticals' Key Shareholder Meeting

Jones Research starts Larimar at buy, cites lead asset nomlabofusp

Universe Pharmaceuticals GAAP EPS of -$3.59, revenue of $12.88M

Universe Pharmaceuticals (UPC) has released an update. Universe Pharmaceuticals has reported a decrease in total assets from $53.3 million to $49.4...

Universe Pharmaceuticals Reports Financial Downturn

Universe Pharmaceuticals (UPC) has released an update. Universe Pharmaceuticals INC successfully conducted its 2024 Annual General Meeting, securin...

Universe Pharmaceuticals Secures Strong Shareholder Backing

Universe Pharmaceuticals (UPC) has released an update. Universe Pharmaceuticals has confirmed its agreement with the contents of Form 6-K filed on ...

Universe Pharmaceuticals Confirms Financial Filing Accuracy

Universe Pharmaceuticals receives non-compliance letter from Nasdaq

Universe Pharmaceuticals (UPC) announced that the Company received a written notification from the Nasdaq Stock Market LLC on October 25, 2024, not...

Universe Pharmaceuticals receives Nasdaq notification over bid price deficiency

Universe Pharmaceuticals (UPC) has released an update. Universe Pharmaceuticals has received a notification from Nasdaq regarding its non-complianc...

Comments

Universe Pharmaceuticals

Universe Pharmaceuticals (UPC) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO